2021 Vault Rankings
At a Glance
“Investment in learning.”
“Strong, supportive, and collegial office culture.”
“Fascinating work, opportunities for growth.”
“The volatility of hours.”
“Deadlines can shift unexpectedly.”
“Leading economics consulting firm.”
“Well-respected litigation consulting.”
“Very intelligent people.”
About Analysis Group, Inc.
Boston-based Analysis Group provides expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, global health care corporations, and government agencies. Much of the firm’s work is grounded in economic analysis – whether that involves a quantitative assessment related to litigation, quantifying the impact of a disease on the U.S. economy, or developing a model for a client’s corporate strategic planning exercise.
Analysis Group has provided litigation support for lawyers at more than 500 global law firms, and has consulted to general counsels and senior executives at a number of Fortune 100 companies. The firm also has a robust health care practice.
For law firms, Analysis Group’s consultants help with pretrial discovery, development of economic and financial models, preparation of testimony, critique of opposing experts’ analyses, and provision of expert testimony. For example, they provided analysis of complex securities – such as derivatives and credit default swaps, or the securitized assets at the center of the subprime housing fallout – both for litigation and for a wide range of participants in financial markets following the financial crisis of 2008. The firm also works on interesting and unusual cases, such as the “Deflategate” controversy.
Corporate and government clients call on the firm for help with a variety of business issues, including company and asset valuations, cost-effectiveness analyses, market and competition analyses, intellectual property matters, and tax issues. The firm’s large and growing health care practice integrates outcomes research, epidemiology, drug safety studies, and pricing and product strategy, as well as litigation support.
Close to – but not inside – the ivory tower
Former Arthur D. Little consultants Bruce Stangle and Michael Koehn founded Analysis Group in 1981 in Belmont, MA. The two Ph.D. economists sought to fuse academic practice with business litigation consulting by applying economic research to distill complex situations into narratives with powerful effect when introduced at trials. Their goal was to create a uniquely collaborative environment. For each client engagement, Analysis Group’s professionals are grouped into teams, which are tailored to the needs of the project and the client. Often, these teams are supplemented by academic or industry experts from the firm’s external network.
At the beginning, the firm primarily consulted on mergers and acquisitions. Today, its consultants – working from 14 offices across the globe – have experience in all areas of economics as it applies to the legal and business world. This includes securities, health care, energy, intellectual property, antitrust, and commercial litigation and damages.
The firm adheres to four operating tenets, which give shape to its business philosophy. The first is access: Analysis Group maintains close ties to specialists – top minds in academia, leaders in their respective industries, and government insiders – to ensure that clients have access to the best people and ideas. Consultants work closely with a network of such experts to offer clients quantitative analysis and hands-on experience to help overcome business and legal hurdles. The second is collaboration: The firm encourages strong relationships within consulting teams and between teams and clients – which ultimately improves communication, effectiveness, and satisfaction. The third is responsiveness: The firm is able to rapidly identify specialized experts for a case, and employs a flexible structure that allows teams to quickly scale up or down as needed. The final tenet is pragmatism: Analysis Group believes all strategies should focus on relevant, applicable solutions in the business or legal world.
In the News
Analysis Group Publishes Research on Employment and GDP Effects of Investment in New Spectrum for 5G Wireless Networks
Analysis Group prepared a white paper to inform the Federal Communications Commission’s (FCC’s) consideration of whether to make additional spectrum available for next-generation 5G wireless networks. 5G will enable improvements in data speed, service quality, and network capacity because it is designed to exploit not only low-band spectrum, which historically has been used for mobile voice and data services, but also mid- and high-band spectrum. Consequently, to achieve the anticipated increases delivered by 5G, service providers will need to invest in building out new infrastructure for each band.
An Analysis Group team, including Principal David Sosa, Vice President Greg Rafert, and Analyst Ethan Brodeur, researched the economic impacts from making low-, mid-, and high-band spectrum available for 5G services. They grouped 5G infrastructure-related capital spending into four industry categories (wireless communications equipment, construction, wireline communications equipment, and wire and cable), and modeled the impact on US GDP and jobs creation.
Based on estimates of nearly $220 billion in new capital expenditures, the team concluded that deploying infrastructure for all three bands of spectrum would add $391 billion in GDP to the US economy and create 1.9 million job-years. Approximately 70 percent of the GDP and jobs impact is attributable to deployment of mid-band spectrum. Another 19 percent is traceable to deployment of high-band spectrum intended for dense metropolitan areas, with the remaining 11 percent coming from deployment of low-band spectrum required for nationwide rural coverage.
Analysis Group Symposium Examines Critical Economic Issues in Life Sciences Litigation
Analysis Group convened a symposium to bring together academic experts, industry counsel, and consultants from the firm for discussions on litigation topics often encountered by pharmaceutical, biotechnology, and medical device companies today. A key goal was to facilitate the exchange of views on critical law and economics questions in a forum that included a variety of stakeholders. David Schmittlein, Dean of the MIT Sloan School of Management, opened the Symposium by noting the many points of connection between Analysis Group and the Sloan School.
One major theme of the gathering was the potential tradeoffs between access to treatments already on the market (affordability), and access to future treatments that have yet to be developed (innovation). That was the issue underlying much of the keynote event that opened the Symposium – a fireside chat between two former commissioners of the Food and Drug Administration: Mark McClellan (now director of the Duke-Margolis Center for Health Policy at Duke University) and Scott Gottlieb (now resident fellow at the American Enterprise Institute). Moderated by Managing Principal Crystal Pike, co-organizer of the Symposium, the discussion between the two former regulators also addressed topics such as the role played by real-world evidence at the approval and post-approval stages; First Amendment issues in the context of off-label promotion investigations; and the distinct challenges faced by private and public payers in trying to provide access to transformative therapies and improve health outcomes.
Many of the themes discussed during the fireside chat also arose during a plenary session on drug pricing introduced by Analysis Group CEO and Chairman Martha Samuelson, and moderated by Managing Principal Noam Kirson. The participants included: Dr. Gottlieb, Rena Conti of Boston University, Craig Garthwaite of Northwestern University, Jennifer Bryant of PhRMA, and David Cutler of Harvard University. The session began with the question of why drug pricing gets so much attention even though drug costs represent only 10–15 percent of health care spending in the United States. This led to discussions concerning innovative approaches to pricing, efforts to regulate and reduce drug prices, and the impact of competition on prices.
111 Huntington Avenue
Boston, MA 02199
Phone: (617) 425-8000
Employer Type: Private
CEO & Chairman: Martha S. Samuelson
Boston, MA (HQ)
Los Angeles, CA
Menlo Park, CA
New York, NY
San Francisco, CA
- Antitrust & Competition
- Class Certification
- Commercial Disputes
- Data Science & Statistical Modeling
- Energy & Environment
- Epidemiology & Biostatistics
- Government & Corporate Investigations
- Health Care
- Intellectual Property
- International Arbitration
- Labor & Employment
- Media, Entertainment & Communications
- Privacy & Data Security
- Securities, Financial Products & Institutions
- Strategy, Policy & Analytics
- Surveys & Experimental Studies
- Tax & Accounting
Transaction & Governance Litigation